Summary In this episode of the Future of Dermatology Podcast, Dr. Faranak Kamangar and Dr. Tina Bhutani discuss the critical issues surrounding equity in dermatological clinical trials, particularly focusing on the underrepresentation of patients with skin of color and those with low body surface area in psoriasis studies. They explore the findings from the Visible and Spectrum trials, emphasizing the need for inclusivity in clinical research and the importance of reevaluating how psoriasis severity is assessed and treated. This conversation highlights the advancements in dermatological therapies and the ongoing challenges in ensuring equitable access to these innovations. Takeaways - There is significant under-representation in dermatology clinical trials.- Patients with skin of color often present with more severe psoriasis due to misdiagnosis.- The Visible trial focused on patients with skin of color to address these disparities.- Recruitment for clinical trials can be improved with targeted efforts.- Insurance companies often dictate treatment options based on outdated criteria.- Patients with low body surface area psoriasis are often overlooked in treatment decisions.- The International Psoriasis Council suggests reevaluating how psoriasis severity is assessed.- Innovations in therapy have outpaced our understanding of treatment criteria.- Empathy is crucial in understanding the impact of skin diseases on patients' lives.- Future dermatological practices must prioritize inclusivity and patient-centered care. Chapters 00:00 - Introduction to Dermatology Innovations02:53 - Equity in Clinical Trials05:40 - The Visible Trial: Addressing Underrepresentation08:38 - The Spectrum Trial: Expanding Patient Inclusion11:46 - Reevaluating Psoriasis Severity and Treatment14:21 - Future Perspectives in Dermatology